Donepezil, rivastigmine, galantamine and memantine for ...

of memantine in patients with moderate to severe
Alzheimer’s disease. Pharmacoeconomics 2003;
21:327–40.
148. Kronborg Andersen C, Nielsen H, Lolk A,
Andersen J, Becker I, Kragh-Sorensen P. Incidence
of very mild to severe dementia and Alzheimer’s
disease in Denmark: the Odense Study. Neurology
1999;52:85–90.
149. Bloom BS, de Pouvourville N, Straus WL. Cost of
illness of Alzheimer’s disease: how useful are
current estimates? Gerontologist 2003;43:158–64.
150. British National Formulary, No. 49 (March).
London: British Medical Association and the Royal
Pharmaceutical Society of Great Britain; 2005.
151. Department of Health. NHS Reference Costs 2002.
URL: http://www.doh.gov.uk/nhsexec/refcosts.htm
152. O’Shea E, O’Reilly S. The economic and social
cost of dementia in Ireland. Int J Geriatr Psychiatry
2000;15:208–18.
153. Stewart A. Donepezil in the treatment of people with
Alzheimer’s disease: a pilot Markov approach.
Discussion paper 1324. PSSRU; 1997.
154. Blackwell J, O’Shea E, Moane G, Murray P.
Care provision and cost measurement: dependent elderly
people at home and in geriatric hospitals. Dublin:
Economic and Social Research Institute; 1992.
155. Hope T, Keene J, Fairburn C, McShane R,
Jacoby R. Behaviour changes in dementia. 2: Are
there behavioural syndromes? Int J Geriatr
Psychiatry 1997;12:1074–8.
156. Hope T, Keene J, Gedling K, Cooper S,
Fairburn C, Jacoby R. Behaviour changes in
dementia. 1: Point of entry data of a prospective
study. Int J Geriatr Psychiatry 1997;12:1062–73.
157. Morris JN, Fries BE, Mehr DR, Hawes C,
Phillips C, Mor V, et al. MDS Cognitive
Performance Scale. J Gerontol 1994;49:M174–82.
158. Souêtre E, Thwaites RM, Yeardley HL. Economic
impact of Alzheimer’s disease in the United
Kingdom. Cost of care and disease severity for
non-institutionalised patients with Alzheimer’s
disease. Br J Psychiatry 1999;174:51–5.
159. NHS funded nursing care in nursing homes: what
it means for you. URL: www.doh.gov.uk/joint/unit/
freenursingcare/residentscarersguide.pdf. Accessed
2004.
160. Alzheimers Society. Paying home care fees.
Information Sheet. London: Alzheimers Society;
2004.
161. Whitehouse P. Measurements of quality of life in
dementia. In Wimo A, Jonsson B, Karlsson G,
Winblad B, editors. Health economics of dementia.
Chichester: John Wiley; 1998. pp. 403–17.
162. Walker MD, Salek SS, Bayer AJ. A review of quality
of life in Alzheimer’s disease. Part 1: Issues in
© Queen’s Printer and Controller of HMSO 2006. All rights reserved.
Health Technology Assessment 2006; Vol. 10: No. 1
assessing disease impact. Pharmacoeconomics 1998;
14:499–530.
163. Leon J, Neumann PJ, Hermann RC, Hsu M-A,
Cummings JL, Doraiswamy PM, et al. Healthrelated
quality-of-life and service utilization in
Alzheimer’s disease: a cross-sectional study. Am J
Alzheimer’s Dis 2000;15:94–108.
164. Neumann PJ, Sandberg EA, Araki SS, Kuntz KM,
Feeny D, Weinstein MC. A comparison of HUI2
and HUI3 utility scores in Alzheimer’s disease.
Med Decis Making 2000;20:413–22.
165. Torrance GW, Feeny DH, Furlon WJ, Barr RD,
Zhang Y, Wang Q. Multi-attribute preference
functions for a comprehensive health status
classification system: Health Utilities Index Mark
2. Med Care 1996;24:702–22.
166. Neumann PJ. Measuring QALYS in dementia.
In Wimo A, Jonsson B, Karlsson G, Winblad B,
editors. Health economics of dementia. Chichester:
John Wiley; 1998. pp. 359–70.
167. Zimmerman SJ, Magaziner J. Methological issues
in measuring the functional status of cognitively
impaired nursing home residents: the use of
proxies and performance based measures.
Alzheimer Dis Assoc Disord 1994;8(Suppl 1):281–90.
168. Kerner DN, Patterson TL, Grant I, Kaplan RM.
Validity of the quality of well-being scale for
patients with Alzheimer’s disease. J Aging Health
1998;10:44–61.
169. Kaplan RM, Anderson JP. A general health policy
model: update and applications. Health Serv Res
1988;23:203–35.
170. Sano M, Albert SM, Tractenberg R, Schittini M.
Developing utilities: quantifying quality of life for
stages of Alzheimer’s disease as measured by the
Clinical Dementia Rating. J Ment Health Aging
1999;5:59–68.
171. Dodge HH, Shen C, Pandav R, DeKosky ST,
Ganguli M. Functional transitions and active life
expectancy associated with Alzheimer disease. Arch
Neurol 2003;60:253–9.
172. Burns A, Lewis G, Jacoby R, Levy R. Factors
affecting survival in Alzheimer’s disease. Psychol
Med 1991;21:363–70.
173. Newcomer R, Covinsky KE, Clay T, Yaffe K.
Predicting 12-month mortality for persons with
dementia. J Gerontol B Psychol Sci Soc Sci 2003;
58:S187–98.
174. Hui JS, Wilson RS, Bennett DA, Bienias JL,
Gilley DW, Evans DA. Rate of cognitive decline
and mortality in Alzheimer’s disease. Neurology
2003;61:1356–61.
175. Lapane KL, Gambassi G, Landi F, Sgadari A,
Mor V, Bernabei R. Gender differences in
predictors of mortality in nursing home residents
with AD. Neurology 2001;56:650–4.
159